Monopar Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Monopar Therapeutics

19/03/2024 12:53

* Monopar Therapeutics Inc  MNPR.OQ   MNPR.O  is expected
to show
no change in quarterly revenue when it reports  results on March
21 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Monopar Therapeutics Inc
is
for a loss of 15 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Monopar
Therapeutics Inc is $8.50​, above​ its last closing price
of $0.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.15       -0.17      -0.14     Beat    17.6
 Jun. 30 2023  -0.18       -0.18      -0.16     Beat    13
 Mar. 31 2023  -0.22       -0.22      -0.19     Beat    14.4​
 Dec. 31 2022  -0.20       -0.20      -0.23     Missed  -12.2
 ​​Sep.        -0.21       -0.22      -0.19     Beat    12.6
 30 2022                                                
 Jun. 30 2022  -0.20       -0.21      -0.22     Missed  -6.4​
 Mar. 31 2022  -0.22       -0.22      -0.19     Beat    14.6
 Dec. 31 2021              -0.19      -0.21     Missed  -10.5
 This summary was machine generated March 19 at 12:53 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)